TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2018

BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study.

Peter A Fasching et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.